SLNSilence Therapeutics plcRunning, no new patients
Study to Assess SLN124 in Patients With Polycythemia Vera
Polycythemia Vera
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 69 (final count)
- Started
- Jan 26, 2023
- Main results expected
- Sep 2026
- Fully finished
- Mar 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Incidence of treatment-emergent adverse events (AEs)
Measured over: Day 239
Phase 1: Assessment of the number of phlebotomies at intervals
Measured over: 6 months prior to dosing to Day 239
Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase)
Measured over: 18 to 36 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05499013 · record last updated 2025-12-19 · checked 2026-11-09 15:47 UTC